We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The FDA shot down AstraZeneca’s Farxiga (dapagliflozin) as an adjunct treatment to insulin for type 1 diabetes patients in a complete response letter to the company on Monday. Read More